The United States and New Zealand are the only developed countries that allow prescription drug advertising directly to consumers. Every other nation bans or heavily restricts it, and for good reason: a growing body of evidence shows that these ads drive up healthcare costs, lead to clinically inappropriate prescriptions, and present a distorted picture of drug risks and benefits.
Doctors Prescribe Drugs They Disagree With
The most direct harm from prescription drug advertising is its effect on what happens in the exam room. When patients ask for a specific drug they saw on television, doctors write that prescription 39 to 77 percent of the time. That sounds like the system working, except for one detail: physicians themselves judge roughly half of those prescriptions to be clinically inappropriate. In one survey of 535 physicians, doctors complied with advertised drug requests 77 percent of the time despite considering 49 percent of them to be the wrong clinical choice.
Why would a doctor prescribe something they don’t believe in? Nearly half of surveyed physicians said they went along with an advertised drug request specifically to accommodate the patient, even though they didn’t think it was the right treatment. The pressure to maintain a good relationship, avoid conflict, and keep patients from doctor-shopping creates a dynamic where advertising effectively overrides clinical judgment.
A more rigorous study using actors trained to present specific symptoms confirmed this pattern. Patients who requested an advertised drug were 16.9 times more likely to leave with a prescription than those who didn’t make a request, even though physicians expressed ambivalence about half of these prescriptions. In that same study, actors presenting with adjustment disorder (a condition not treated with medication) still received inappropriate prescriptions 34 percent of the time when they requested an advertised drug. The advertising didn’t just encourage treatment. It encouraged the wrong treatment.
Ads Promote Lower-Value Drugs
If drug companies were advertising genuine breakthroughs, the case against these ads would be weaker. But the evidence points in the opposite direction. A 2023 study published in the JAMA Network examined the 150 top-selling prescription drugs in the U.S. and found that drugs rated as having lower added clinical benefit devoted a significantly larger share of their promotional budget to consumer advertising. Specifically, drugs with low benefit ratings allocated an absolute 14.3 percent more of their promotional spending to direct-to-consumer ads compared to drugs with high benefit ratings.
This makes strategic sense for manufacturers. A drug that represents a clear clinical advance sells itself through medical channels. Doctors learn about it, prescribe it, and patients benefit. But a drug that offers little improvement over existing options needs a different sales strategy: go directly to the consumer, build brand recognition, and let patient demand do the work. The result is a system where the drugs you see advertised most aggressively tend to be the ones that offer the least improvement over what’s already available.
Brand-Name Prices and the Cost Problem
Advertised drugs are almost always brand-name products, and the price gap between brand-name and generic drugs is enormous. According to FDA data, generic drugs cost 51 to 60 percent less than their brand-name equivalents on average. When four or more generic competitors exist, prices drop by 79 percent. With six or more, prices fall by over 95 percent.
Advertising steers patients toward expensive brand-name options when cheaper, equally effective generics may be available. A patient who walks into a doctor’s office asking for a specific brand they saw during a commercial is unlikely to accept “there’s a generic that does the same thing” without some resistance. The entire point of the ad was to create preference for that brand. This drives up spending for individual patients, insurance plans, and the healthcare system as a whole, often without any corresponding improvement in outcomes.
Risk Information Gets Buried
Before 1997, prescription drug ads on television were rare because federal rules would have required companies to read lengthy safety information on air. That year, the FDA created a workaround: companies could recite a brief “major risk statement” and direct viewers to a website, phone number, or print ad for the full details. This opened the floodgates for broadcast advertising while ensuring that most consumers would never encounter the complete risk profile of the drugs being marketed to them.
Even with these relaxed rules, drug companies frequently push the boundaries. An analysis of FDA warning letters to pharmaceutical manufacturers found that omission or minimization of risk information was the single most common violation, accounting for 30.6 percent of all cited violations. The next most common was overstating efficacy or making unsubstantiated claims about how well the drug works (18.6 percent), followed by broadening the drug’s indicated uses beyond what was approved (13.7 percent) and making unsupported superiority claims over competitors (13.1 percent). In total, nearly 79 percent of violations involved misleading clinical claims.
These aren’t occasional slip-ups. They reflect a systematic pattern in which the commercial incentive to sell drugs conflicts with the regulatory requirement to present balanced information.
Turning Normal Life Into a Diagnosis
Drug advertising doesn’t just promote treatments for existing conditions. It can reshape how people think about their own health. Medicalization, the process of reframing ordinary human experiences as medical problems requiring treatment, is a well-documented concern in medical sociology. Ads that ask “Do you ever feel tired?” or “Do you sometimes feel anxious in social situations?” encourage viewers to interpret common, often temporary experiences as symptoms of a diagnosable condition.
This serves the pharmaceutical industry’s interests by expanding the potential market for a drug. If shyness becomes “social anxiety disorder” and occasional sadness becomes “depression,” the pool of people who might request a prescription grows substantially. The line between raising awareness of genuine undertreated conditions and manufacturing demand for unnecessary medication is blurry, and advertising companies have every financial incentive to push that line as far as it will go.
The Doctor-Patient Relationship Suffers
When a patient arrives with a specific drug in mind, the visit changes. Instead of an open conversation about symptoms and treatment options, the appointment becomes a negotiation. The doctor must either explain why the advertised drug isn’t right (risking patient dissatisfaction) or prescribe something they have reservations about (compromising their clinical standards). Neither outcome is good.
This dynamic erodes trust in both directions. Patients who are denied a requested drug may feel their doctor isn’t listening. Doctors who feel pressured to prescribe against their judgment may grow cynical about patient interactions. The data showing that 48 percent of physicians prescribe drugs they disagree with to keep patients happy suggests this tension is widespread and unresolved. In a system where advertising didn’t exist, these conflicts simply wouldn’t arise, and both doctor and patient could focus on finding the best treatment rather than debating the merits of a television commercial.
Why Most Countries Ban It
The fact that only two developed nations permit direct-to-consumer prescription drug advertising is itself a powerful data point. Countries like Australia explicitly prohibit it by law. The European Union, Canada, and virtually every other high-income nation have concluded that the risks to public health outweigh any informational benefit these ads might provide. Opposition within the U.S. and New Zealand has grown steadily among both the public and physicians, with organizations like the American Medical Association calling for restrictions.
The core argument for these ads has always been that they empower patients with information. But the evidence suggests they empower patients with selective, commercially motivated information that leads to more expensive drugs, more inappropriate prescriptions, and a distorted understanding of both benefits and risks. The rest of the world looked at that tradeoff and decided it wasn’t worth it.